Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $10.80 Average PT from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $10.80.

Several research analysts recently commented on the company. Weiss Ratings upgraded Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday.

Insider Buying and Selling at Xeris Biopharma

In related news, insider Beth Hecht sold 16,666 shares of Xeris Biopharma stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $8.01, for a total value of $133,494.66. Following the completion of the sale, the insider owned 1,144,462 shares in the company, valued at approximately $9,167,140.62. The trade was a 1.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 15,000 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $8.02, for a total transaction of $120,300.00. Following the transaction, the insider owned 1,676,126 shares in the company, valued at $13,442,530.52. This trade represents a 0.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 266,499 shares of company stock valued at $1,996,417. Corporate insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

Large investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of Xeris Biopharma in the 2nd quarter worth approximately $115,042,000. UBS Group AG raised its position in shares of Xeris Biopharma by 682.4% during the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock valued at $14,511,000 after acquiring an additional 1,554,869 shares in the last quarter. Vanguard Group Inc. lifted its stake in Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after purchasing an additional 1,358,760 shares during the last quarter. Qube Research & Technologies Ltd lifted its stake in Xeris Biopharma by 67.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after purchasing an additional 1,245,188 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the period. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

Xeris Biopharma stock opened at $7.93 on Friday. Xeris Biopharma has a 12-month low of $5.25 and a 12-month high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -72.09 and a beta of 0.66. The firm’s fifty day moving average price is $7.68 and its 200 day moving average price is $6.80.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%. On average, research analysts forecast that Xeris Biopharma will post 0.03 EPS for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.